MSD has opened a major new technology centre in Hyderabad, India, strengthening the city's position as a global hub for life sciences, artificial intelligence, and advanced technology. The 250,000-square-foot Technology Centre represents a significant expansion of MSD's technology presence in the country and reflects the pharmaceutical industry's growing reliance on digital capabilities to support research, operations, and healthcare innovation.
The centre will bring together capabilities spanning artificial intelligence, data analytics, digital technology, and engineering to support MSD's global Human Health business. By bringing these disciplines together within a dedicated technology facility, MSD aims to strengthen its ability to develop and deploy digital solutions across its global operations, while taking advantage of Hyderabad's deep pool of technology and life-sciences talent.
The investment comes as pharmaceutical companies increasingly integrate advanced technologies into areas ranging from research and drug development to commercial operations and patient engagement. AI and data analytics are becoming particularly important as companies generate and analyse growing volumes of biological, clinical, and operational data, creating demand for specialised teams capable of translating that information into practical tools and insights.
Hyderabad's Growing Technology Role
MSD's expansion also reinforces Hyderabad's emergence as an important global capability centre for the life-sciences industry. The city is home to more than 2,000 life-sciences companies, spanning pharmaceuticals, biotechnology, research, technology, and related services. Its combination of scientific expertise, engineering talent, technology infrastructure, and established pharmaceutical manufacturing capabilities has increasingly attracted multinational companies seeking to build global research and technology operations.
The development aligns closely with the Telangana government's 2026–30 life-sciences policy, which aims to attract 100 global capability centres and create approximately 400,000 direct and indirect jobs. The strategy reflects the state's ambition to move beyond its traditional strengths in pharmaceutical manufacturing and establish itself as a centre for higher-value activities including research, technology, innovation, digital transformation, and global business services.
From Manufacturing to Innovation
Telangana's strategy mirrors a broader transformation taking place across the pharmaceutical sector, where the boundaries between life sciences and technology are becoming increasingly blurred. Pharmaceutical companies are investing not only in laboratories and manufacturing facilities, but also in AI, cloud infrastructure, data science, software engineering, and digital platforms that can accelerate scientific discovery and improve the efficiency of complex global operations.
MSD's Hyderabad centre therefore represents more than an expansion of the company's physical footprint. It is part of a wider shift toward building technology capabilities closer to major pools of scientific and engineering talent, while giving emerging life-sciences hubs a greater role in global innovation. As AI becomes increasingly embedded across the pharmaceutical value chain, investments of this kind could help reshape Hyderabad from a major manufacturing and services centre into an increasingly important destination for AI-enabled pharmaceutical innovation.